Costs of pain in rheumatology

Reumatismo

Volumn 66, Issue 1, 2014, Pages 103-107

  Marsico, Antonio ^a   Atzeni, F ^b   Piroddi, A ^c   Cazzola, M ^d   Stisi, S ^e   Sarzi Puttini, P ^b  

^a SS Annunziata Hospital   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c AISF ^*  (Italy)

^d BUSTO ARSIZIO HOSPITAL   (Italy)

^e Rheumatology Unit G Rummo   (Italy)

Author keywords

Chronic pain; Direct costs; Indirect costs; Intangible costs

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CYCLOOXYGENASE 2 INHIBITOR; DULOXETINE; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PREGABALIN; ANALGESIC AGENT; ANTIRHEUMATIC AGENT;

ABSENTEEISM; CHRONIC PAIN; COST; DIRECT COST; DISEASE ASSOCIATION; DRUG COST; FIBROMYALGIA; GOVERNMENT REGULATION; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH CARE QUALITY; HEALTH CARE UTILIZATION; HUMAN; INDIRECT COST; OSTEOARTHRITIS; PALLIATIVE THERAPY; PRESCRIPTION; QUALITY OF LIFE; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; STAFF TRAINING; ACUTE PAIN; COMPLICATION; COST OF ILLNESS; ECONOMICS; EUROPE; FEE; HEALTH CARE PLANNING; HEALTH SERVICE; ITALY; MUSCULOSKELETAL PAIN; RHEUMATIC DISEASES; UNITED STATES; UTILIZATION;

ACUTE PAIN; ANALGESICS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CHRONIC PAIN; COST OF ILLNESS; DRUG COSTS; EUROPE; FIBROMYALGIA; HEALTH EXPENDITURES; HEALTH POLICY; HEALTH RESOURCES; HEALTH SERVICES NEEDS AND DEMAND; HUMANS; ITALY; MUSCULOSKELETAL PAIN; OSTEOARTHRITIS; PRESCRIPTION FEES; QUALITY OF LIFE; RHEUMATIC DISEASES; UNITED STATES;

EID: 84902155720     PISSN: 00487449     EISSN: 22402683     Source Type: Journal    
DOI: 10.4081/reumatismo.2014.771     Document Type: Review

References (23)

1. Fanelli G, Ventrigli G. Il dolore cronico in medicina generale. 2010: Available from: http:// www.salute.gov.it/
2. Sarzi-Puttini P, Vellucci R, Zuccaro SM, Cherubino P, Labianca R, Fornasari D. The appropriate treatment of chronic pain. Clin Drug Investig. 2012; 32: 21-33.
3. The American Academy of Pain Medicine (AAPM). Incidence of pain, as compared to major conditions. In: AAPM facts and figures on pain. Available from: http://www. painmed.org/patientcenter/facts_on_pain. aspx#incidence
4. The British Pain Society. FAQs. Available from: http://www.britishpainsociety.org/media_ faq.htm
5. Coaccioli S, Varrassi G, Marinangeli F, Aurilio C, Finco G, Gatti A, Geppetti Pet al. An ethics code for pain. Eur J Pain. 2012; 16: 1081-3.
6. Croft P, Blyth FM, van der Windt D, eds. Chronic pain epidemiology: from aetiology to public health. Oxford: Oxford Univ Press; 2010.
7. Italian Regulation. Legge 15 marzo 2010, n.
8. Disposizioni per garantire l'accesso alle cure palliative e alla terapia del dolore. In: G.U. no. 65, 19/03/2010. Available from: http:// www.parlamento.it/parlam/leggi/10038l.htm
9. The Societal Impact of Pain (SIP). A multistakeholder platform in Europe. Available from: http://www.sip-platform.eu
10. Arthritis Care. Pain proposal improving the current and future management of chronic pain. 2010. Available from: http://www.arthritiscare. org.uk/
11. Centre for Economic and International Studies (CEIS). Il futuro del Servizio Sanitario in Europa e in Italia. I report di Economist e CEIS Tor Vergata. Il Sole 24 Ore-Sanità. 2012; 40: 1-45. Available from: http://www.jlive.it/ SurveyScenari/img/futuro_servizio_sanitario_ CEIS.pdf
12. Zheltoukhova K. Musculoskeletal disorders and work. Results of a survey of individuals living with musculoskeletal disorders in six European countries. London: The Work Foundation; 2013. Available from: http://www.fitforworkeurope. eu/FFW_Patient_Survey_FINAL_ 2013.pdf
13. ISTAT. Il benessere equo e sostenibile.2013. Available from: http://demo.istat.it/bilmens-2013gen/index.html
14. Colombo GL, Caruggi M, Serra G, Vinci M. Management of acute pain in Italy. Economic aspects and quality of life. Recenti Prog Med. 2005; 96: 7-15.
15. Scuola Superiore Sant'Anna. Studio sui costi economici e sociali dell'artrite reumatoide. Turchetti G. Available from: http://www.sssup. it/
16. Leardini G. I costi della sindrome fibromialgica. Fibromialgia. Atti convegno 2009 Bologna. pp 271-275.
17. Knight T, Schaefer C, Chandran A, Zlateva G, Winkelmann A, Perrot S. Health-resource use and costs associated with fibromyalgia in France, Germany, and the United States. Clinicoecon Outcomes Res. 2013; 5: 171-80.
18. Sun P, Peng X, Sun S, Novick D, Faries DE, Andrews JS, et al. Direct medical costs and medication compliance among fibromyalgia patients: duloxetine initiators vs. pregabalin initiators. Pain Pract. 2014; 14: 22-31.
19. Altomonte L, Atzeni F, Leardini G, Marsico A, Gorla R, Casale R. Fibromyalgia syndrome: preventive, social and economic aspects. Reumatismo. 2008; 60: 70-8.
20. Pharmastar. Consumo dei farmaci. Comunicato stampa. Aprile 2013. Available from: http:// www.pharmastar.it
21. Federfarma. Consumo farmaci. Aprile 2013. Available from: http://www.federfarma.it
22. Farmindustria. Report consumo dei farmaci. Available from: http://www.farmindustria.it
23. Goldstein J. Healthcare resource utilization and economic impact of a ≥2 g/dL decrease in hemoglobin after NSAID treatment in osteoarthritis patients. DDW 2012; abstract 481.